Background Small interfering RNA (siRNA) gene therapy is a new molecular approach in the search for an efficient therapy for Alzheimer disease (AD), based on the principle of RNA interference. mRNA and protein expression were observed after the cells were transfected with BACE1 siRNA. Conclusions Delivery of BACE1 siRNA appears to specifically reduce the cleavage of APP by inhibiting BACE1 activity. (introduction of nucleic HOX1I acids or proteins into cells offers great possibilities in many different branches of biological and biomedical study, and there are many methods of doing this. Transport of macromolecules across the blood-brain barrier (BBB) requires both specific and nonspecific interactions between macromolecules and proteins/receptors expressed on the luminal and/or the abluminal surfaces of the brain capillary endothelial cells. Endocytosis and transcytosis play important roles in the distribution of macromolecules. Transfection of chemically synthesized short interfering RNAs (siRNAs) enables a high level of sequence-specific gene silencing. Although siRNA design algorithms have been improved in recent years, it is still necessary to confirm the functionality of a CYC116 given siRNA experimentally. siRNA therapy is a new molecular approach in the search for efficient AD therapy based on the principle of RNA interference. Some studies using RNA interference (RNAi) technology have examined the ability of siRNA to silence BACE. Previous findings have shown that no apparent adverse effects are CYC116 observed in BACE1-deficient mice [31,32]. Kao et al. reported that BACE1 siRNA specifically influences the -cleavage of APP and may be a potential therapeutic approach for treating AD. Suppression of BACE1 expression by siRNA was not found to change the subcellular distribution of APP and Presenilin 1, indicating that loss of BACE1 elicits no profound cellular defects . This finding confirms that BACE 1 is a potential therapeutic target for the treatment of AD. Dong et al.  observed that treatment with BACE and APP siRNAs can decrease levels of BACE, full-length APP, and APP c-terminal fragments. In another study, a pAZLDC2 vector was constructed to deliver the siRNA for silencing the BACE 1 gene . The directed delivery of bioactive reagents into cells is one of the most intensely pursued objectives in biomedical research, yet few major breakthroughs have occurred that can be broadly applied in both laboratory research and therapeutic applications. Receptor- mediated delivery is based on simple biological principles and uses existing ligand-induced internalization pathways to deliver a wide variety of biomedically active molecules into the cytoplasm and the nucleus [36,37]. Kossiakoff et al.  developed a robust delivery method for the transport CYC116 of proteins to the cytoplasm of mammalian cells without compromising the integrity of the cell membrane, using a variant of substance P, a neuropeptide that is rapidly internalized upon interaction with the neurokinin-1 receptor (NK1R). Zhang et al.  reported a new strategy for cell-type-specific delivery of functional siRNAs into folate receptor-expressing cells. The described method involves the non-covalent attachment of siRNAs to ligand-conjugated oligodeoxynucleotides via nucleic acid base-paired interactions. Today’s research uses receptor-mediated delivery to present BACE1 siRNA to cells. BACE1 siRNA was conjugated with an opioid-peptide complicated, which was sent to stable INR-32-APP human neuroblastoma cells then. The outcomes demonstrate which the opioid-BACE1-siRNA-1 build destined to opioid receptors in individual neuroblastoma cells and internalized. After BACE1-siRNA-1 internalization, no significant transformation was observed in BACE-1 mRNA appearance, but a 3.5-fold reduction was seen in the protein level. The expression of APP protein and mRNA doubled after transfection of INR-32-APP cells with the opioid-BACE-siRNA-1 construct. Our results present that the build was sent to the examined cells destined with the precise opioid.